title: The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.
abstract: BACKGROUND
  The international standard radiotherapy schedule for early breast cancer delivers 50 Gy in 25 fractions of 2.0 Gy over 5 weeks, but there is a long history of non-standard regimens delivering a lower total dose using fewer, larger fractions (hypofractionation). We aimed to test the benefits of radiotherapy schedules using fraction sizes larger than 2.0 Gy in terms of local-regional tumour control, normal tissue responses, quality of life, and economic consequences in women prescribed post-operative radiotherapy.
  
  
  METHODS
  Between 1999 and 2001, 2215 women with early breast cancer (pT1-3a pN0-1 M0) at 23 centres in the UK were randomly assigned after primary surgery to receive 50 Gy in 25 fractions of 2.0 Gy over 5 weeks or 40 Gy in 15 fractions of 2.67 Gy over 3 weeks. Women were eligible for the trial if they were aged over 18 years, did not have an immediate reconstruction, and were available for follow-up. Randomisation method was computer generated and was not blinded. The protocol-specified principal endpoints were local-regional tumour relapse, defined as reappearance of cancer at irradiated sites, late normal tissue effects, and quality of life. Analysis was by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN59368779.
  
  
  RESULTS
  1105 women were assigned to the 50 Gy group and 1110 to the 40 Gy group. After a median follow up of 6.0 years (IQR 5.0-6.2) the rate of local-regional tumour relapse at 5 years was 2.2% (95% CI 1.3-3.1) in the 40 Gy group and 3.3% (95% CI 2.2 to 4.5) in the 50 Gy group, representing an absolute difference of -0.7% (95% CI -1.7% to 0.9%)--ie, the absolute difference in local-regional relapse could be up to 1.7% better and at most 1% worse after 40 Gy than after 50 Gy. Photographic and patient self-assessments indicated lower rates of late adverse effects after 40 Gy than after 50 Gy.
  
  
  CONCLUSIONS
  A radiation schedule delivering 40 Gy in 15 fractions seems to offer rates of local-regional tumour relapse and late adverse effects at least as favourable as the standard schedule of 50 Gy in 25 fractions.
authors: S M
authors: SM
authors: Bentzen
authors: R K
authors: RK
authors: Agrawal
authors: E G A
authors: EG
authors: Aird
authors: J M
authors: JM
authors: Barrett
authors: P J
authors: PJ
authors: Barrett-Lee
authors: S M
authors: SM
authors: Bentzen
authors: J M
authors: JM
authors: Bliss
authors: J
authors: J
authors: Brown
authors: J A
authors: JA
authors: Dewar
authors: H J
authors: HJ
authors: Dobbs
authors: J S
authors: JS
authors: Haviland
authors: P J
authors: PJ
authors: Hoskin
authors: P
authors: P
authors: Hopwood
authors: P A
authors: PA
authors: Lawton
authors: B J
authors: BJ
authors: Magee
authors: J
authors: J
authors: Mills
authors: D A L
authors: DA
authors: Morgan
authors: J R
authors: JR
authors: Owen
authors: S
authors: S
authors: Simmons
authors: G
authors: G
authors: Sumo
authors: M A
authors: MA
authors: Sydenham
authors: K
authors: K
authors: Venables
authors: J R
authors: JR
authors: Yarnold
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D016016:Proportional Hazards Models; D011788:Quality of Life; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy / Q000592:standards*; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D006113:United Kingdom